INFLAMmatory BiomarkErs in COVID-19 Participants and Severity of Disease

Status unconfirmed

Conditions studied: COVID-19

In brief

Observational Study of the Association of Immunological and Inflammatory Biomarkers in COVID-19 Naïve and Infected Participants and Severity of Disease. Thirty naive and 30 COVID positive participants will have a blood sample taken after informed consent and be assessed for COVID symptoms according to WHO classification. Participants will be followed monthly for 6 months. At each contact, participants will be assessed for COVID symptoms and progress since the previous visit.

Key facts

Study ID

NCT05175846

Run by

Trinitas Global, LLC

People needed

60

Starts

2022-04-01

Expected to finish

2023-06-30

Last updated by the study team

2022-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent (IC) within 4 days of COVID-19 test.
• Age 18 or older
• COVID-19 test
• Group 1: negative COVID-19 test Group 2: positive COVID-19 test with Severe or Critical symptoms of disease (per WHO Guidance).

You may not qualify if…

• Any autoimmune disease or immune-modulator therapy.
• Mild or Moderate symptoms of COVID-19 disease (per WHO Guidance).

Where it is running

• St Francis Hospital — Wilmington, Delaware, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.